Effect of the angiotensin receptor–neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide

AIMS: Sacubitril/valsartan is indicated for the treatment of heart failure and reduced ejection fraction (HFrEF). Furosemide, a loop diuretic commonly used for the treatment of HFrEF, may be coadministered with sacubitril/valsartan in clinical practice. The effect of sacubitril/valsartan on the phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayalasomayajula, Surya, Schuehly, Uwe, Pal, Parasar, Chen, Fabian, Zhou, Wei, Sunkara, Gangadhar, Langenickel, Thomas H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Pharmacokinetic Dynamic Relationships
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903241/
https://www.ncbi.nlm.nih.gov/pubmed/29318651
http://dx.doi.org/10.1111/bcp.13505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903241/
https://www.ncbi.nlm.nih.gov/pubmed/29318651
http://dx.doi.org/10.1111/bcp.13505

Ejemplares similares